...
首页> 外文期刊>Journal of cellular biochemistry. >Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines
【24h】

Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines

机译:双硫仑/铜-双硫仑损害食管鳞癌细胞系中二甲双胍增强多种蛋白质降解和周转途径,并增强细胞毒性。

获取原文
获取原文并翻译 | 示例
           

摘要

Disulfiram (DSF), used since the 1950s in the treatment of alcoholism, is reductively activated to diethyldithiocarbamate and both compounds are thiol-reactive and readily complex copper. More recently DSF and copper-DSF (Cu-DSF) have been found to exhibit potent anticancer activity. We have previously shown that the anti-diabetic drug metformin is anti-proliferative and induces an intracellular reducing environment in oesophageal squamous cell carcinoma (OSCC) cell lines. Based on these observations, we investigated the effects of Cu-DSF and DSF, with and without metformin, in this present study. We found that Cu-DSF and DSF caused considerable cytotoxicity across a panel of OSCC cells, and metformin significantly enhanced the effects of DSF. Elevated copper transport contributes to DSF and metformin-DSF-induced cytotoxicity since the cell-impermeable copper chelator, bathocuproinedisulfonic acid, partially reversed the cytotoxic effects of these drugs, and interestingly, metformin-treated OSCC cells contained higher intracellular copper levels. Furthermore, DSF may target cancer cells preferentially due to their high dependence on protein degradation/turnover pathways, and we found that metformin further enhances the role of DSF as a proteasome inhibitor. We hypothesized that the lysosome could be an additional, novel, target of DSF. Indeed, this acid-labile compound decreased lysosomal acidification, and DSF-metformin co-treatment interfered with the progression of autophagy in these cells. In summary, this is the first such report identifying the lysosome as a target of DSF and based on the considerable cytotoxic effects of DSF either alone or in the presence of metformin, in vitro, and we propose these as novel potential chemotherapeutic approaches for OSCC. J. Cell. Biochem. 116: 2334-2343, 2015. (c) 2015 Wiley Periodicals, Inc.
机译:自1950年代以来用于治疗酒精中毒的双硫仑(DSF)已被还原活化为二乙基二硫代氨基甲酸酯,并且两种化合物均为硫醇反应性且易于络合的铜。最近,已经发现DSF和铜-DSF(Cu-DSF)表现出有效的抗癌活性。我们以前已经表明,抗糖尿病药物二甲双胍具有抗增殖作用,并在食道鳞状细胞癌(OSCC)细胞系中诱导细胞内还原环境。基于这些观察,在本研究中,我们研究了含或不含二甲双胍的Cu-DSF和DSF的作用。我们发现Cu-DSF和DSF在一组OSCC细胞中引起相当大的细胞毒性,二甲双胍显着增强了DSF的作用。铜转运的增加有助于DSF和二甲双胍-DSF诱导的细胞毒性,因为不可渗透细胞的铜螯合剂,浴铜二磺酸,部分逆转了这些药物的细胞毒性作用,有趣的是,用二甲双胍处理的OSCC细胞含有更高的细胞内铜水平。此外,由于DSF高度依赖于蛋白质降解/转变途径,因此它们可能优先靶向癌细胞,并且我们发现二甲双胍进一步增强了DSF作为蛋白酶体抑制剂的作用。我们假设溶酶体可能是DSF的另一个新靶标。实际上,这种对酸不稳定的化合物降低了溶酶体的酸化作用,并且DSF-二甲双胍的共同治疗干扰了这些细胞中自噬的进程。总之,这是首次将溶酶体鉴定为DSF的靶标,并基于DSF单独或在存在二甲双胍的条件下在体外对DSF的显着细胞毒性作用,我们建议将其作为OSCC的新型潜在化学治疗方法。 J.细胞。生化。 116:2334-2343,2015。(c)2015 Wiley Periodicals,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号